STOCK FOCUS OF THE DAY
Genting Bhd : Gives funding to medical software
developer HOLD
According to news reports, Genting Bhd has provided medical
software developer CorTechs Labs, Inc with financing to support the company’s
growth. According to sources on the Internet, the size of the funding was
US$1.2mil.
CorTechs is the developer of a leading software solution for
the quantification of volumetric brain atrophy, which can help diagnose a
variety of brain disorders. The software NeuroQuant is used by hundreds of
neurologists, radiologists, and clinical researchers in the world. Bloomberg
reported that the funding given to CorTechs by Genting Bhd will help accelerate
the development of CorTechs’ industry-changing image analysis software and
expand its sales and marketing initiatives.
We are neutral on this development. The size of funding of
US$1.2mil is not large. This is not Genting Bhd’s first foray into
pharmaceuticals. Genting Bhd has also been investing in associate stakes in
various companies in the past.
In December 2013, Genting Bhd bought an 8.4% in Linc Energy
for S$57.4mil. Linc Energy has a portfolio of oil, gas and coal assets and
underground coal gasification technology. In November 2012, Genting Bhd
invested US$111.8mil in a 20% stake in TauRx Pharmaceuticals. In 2010, Genting
Bhd acquired a 20% stake in Union Bank of Colombo, Sri Lanka for
RM27mil.
We believe that Genting Bhd’s company level cash is more
than RM1bil. We reckon that the cash reserves would be used to partly finance
the Banten Power Plant in Java, which will cost RM1bil. In addition, we believe
that part of the cash would be allocated for the equity portion of the “Resorts
World Las Vegas” project. Phase 1 of the project is estimated to cost US$2-3bil.
Maintain HOLD on Genting Bhd.
NEWS HIGHLIGHTS
Property Sector : Country Garden, KPRJ plan massive
reclamation development for luxury homes
Automotive Sector : Passenger, commercial vehicle sales up
12.6%
Plantation Sector : Full mandate of B5 biodiesel use soon
Plantation Sector : Malaysia increases CPO export tax
DISCLAIMER:
The information and opinions in this report were prepared by
AmResearch Sdn Bhd. The investments discussed or recommended in this report may
not be suitable for all investors. This report has been prepared for
information purposes only and is not an offer to sell or a solicitation to buy
any securities. The directors and employees of AmResearch Sdn Bhd may from time
to time have a position in or with the securities mentioned herein. Members of
the AmInvestment Group and their affiliates may provide services to any company
and affiliates of such companies whose securities are mentioned herein. The
information herein was obtained or derived from sources that we believe are
reliable, but while all reasonable care has been taken to ensure that stated
facts are accurate and opinions fair and reasonable, we do not represent that
it is accurate or complete and it should not be relied upon as such. No
liability can be accepted for any loss that may arise from the use of this
report. All opinions and estimates included in this report constitute our
judgement as of this date and are subject to change without notice.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.